Based on WHO criteria, osteopenia was diagnosed in 264 patients (53.7%), 54.6% among men [95% confidence interval (CI), 49.4–59.7) and 51.1% among women (95% CI, 42.6–59.6). Osteopenia was diagnosed in 50.0% (95% CI, 40.0–60.0) and 54.8% (95% CI, 37.5–72.5) of premenopausal and menopausal women, respectively. Osteoporosis was diagnosed in 132 patients (26.8%), 33.7% among men (95% CI, 28.8–38.6) and 8.3% among women (95% CI, 3.6–13.0). Osteoporosis was diagnosed in 3.9% (95% CI, 0.2–7.8) and 22.6% (95% CI, 7.9–37.3) of premenopausal and menopausal women, respectively. Table 3 shows the distribution of median BMD according to gender, site and patients' diagnostic category. Osteoporosis predominated at the femoral neck for men (median BMD, 0.66 g/cm2) and for women (median BMD, 0.59 g/cm2).
Correlates of low bone density
Among men, the following factors significantly associated with the diagnosis of bone mass loss in the univariable model were included in the multivariable analysis: age, follow-up time since HIV diagnosis, transmission group, AIDS clinical stage, HIV plasma viral load < 500 copies/ml, log-based plasma viral load, tobacco consumption, physical activity, cumulative exposure to antiretroviral drug class, BMI < 20.6 kg/m2 and lipodystrophy. Independent factors associated with the diagnosis of osteoporosis were older age, homosexual HIV transmission, low BMI and HIV plasma viral load < 500 copies/ml (Table 4). Only older age and lower BMI were marginally associated with osteopenia (Table 4). In women, all bone disorders were pooled without distinction between osteopenia and osteoporosis because of the lower number of observations in each subgroup. Factors analysed in the multivariable model were menopausal status, age, follow-up time since HIV diagnosis, transmission group, AIDS clinical stage, HIV plasma viral load < 500 copies/ml, log-based plasma viral load zenith, CD4 lymphocyte count nadir, alcohol consumption, calcium intake > 1 g/day, physical activity, cumulative exposure to antiretroviral drug class and lipodystrophy. Older age [odds ratio (OR), 1.69; 95% CI, 1.10–2.60; P = 0.02] and low CD4 cell count nadir (OR, 1.43; 95% CI, 1.10–1.85; P = 0.008) were identified as factors associated with reduced BMD. To explore further whether the association between low HIV plasma RNA and osteoporosis in men was related to antiretroviral exposure, the effect of cumulative exposure to HAART was analysed without adjustment for HIV plasma RNA. Three different multivariable models were developed but in none was the treatment variable effect significant: cumulative exposure to any antiretroviral drug (OR, 1.01; 95% CI, 1.00–1.02; P = 0.07), cumulative exposure to HAART (OR, 1.02; 95% CI, 0.95–1.10; P = 0.58), and naive versus drug experienced status (OR, 0.28; 95% CI, 0.06–1.31; P = 0.11). Furthermore, this analysis was carried out for each drug class, again without being significant: cumulated NRTI (OR, 1.01; 95% CI, 1.00–1.02; P = 0.06), cumulated NNRTI (OR, 1.01; 95% CI, 1.00–1.03, P = 0.43) and cumulated PI (OR, 1.01; 95% CI, 1.00–1.03; P = 0.09).
This cross-sectional survey within the Aquitaine cohort of HIV-infected patients was conducted to estimate the prevalence of BMD disorders and to investigate associated factors. Among the 492 patients, representative of the Aquitaine cohort, who were recruited, the percentage of bone abnormalities was 80.5%, with 53.7% osteopenia and 26.8% osteoporosis. Osteoporosis prevalence was high in spite of the young age of the population and reflected well the early demineralization problem faced by HIV-infected patients. This frequency is higher than that reported in other studies, which had prevalence rates ranging from 0% to 22% [11,13,18,22–31], with narrow boundaries.
Another interesting finding of this osteodensitometry-based survey is the site of bone demineralization. For men, there is preferentially cortical anatomic osteoporosis, whereas for women, there are trabecular abnormalities. Apart from HIV disease, male osteoporosis in normal populations has a cortical predominance, especially in secondary osteoporosis, whereas for women, the postmenopausal osteoporosis is classically trabecular, first involving the spine. The few studies that have described BMD abnormalities according to the anatomic site have been inconclusive [4,17,24].
The main strength of our study is the relatively large number of patients included and the number of pathological fractures (10.2%). No publication provides such an estimate and we could only identified some individual case reports . The potential impact of BMD reduction on fracture risk remains unclear for HIV-infected patients. This may be because the majority are young, have few visual or balance problems and are not prone to falls. As the HIV-infected population gets older, clinicians may see an increase in the fracture rate.
The main limitation in the interpretation of our report is the absence of French references for the T-score for men. This could explain the surprising high male prevalence of BMD disorders detected in our group. There is a French reference of BMD values for women, but an American database had to be used for males in the three anatomic sites. Consequently, we may have overestimated the frequency of male osteoporotic events, because Americans have a diet that is richer in vitamin D than the French and so have a higher bone mineralization peak. By using an American reference, we are perhaps overinterpreting the BMD results from the whole body and the femoral neck. For males, we have compared the T-scores obtained for the spine here based on data in American databases with the T-scores that we would have obtained using French databases, in order to see if the use of a non-French reference database was important, and found no statistical significance between the two sets of T-scores (data not shown). The gender stratification, imposed by the difference in reference frame between men and women, led to a loss in statistical power of the study as it generated two weaker samples statistically. This element partly explains the low number of associated factors highlighted in multivariate analysis.
Among the factors found to be associated with BMD, some were expected, such as older age or lower BMI, but others are described for the first time, such as homosexual HIV transmission group, low HIV plasma RNA and low CD4 cell count nadir. The link with homosexual transmission group could indicate that this is a proxy for the abuse of substances that might be toxic for bone metabolism or coinfection, such as human herpes virus 8 and Kaposi disease. Our finding of higher risk of BMD disorder with low plasma viral load does not agree with some previously published reports [15,18], which hypothesized a potential role of the virus itself. In our study, low plasma viral load was the consequence of successful reduction of viral replication with antiretroviral drug exposure. This indicates, indirectly, a bone harmful effect of treatment itself; however, the investigations of the effect of the antiretroviral treatment, unadjusted for the plasma viral load, did not show a significant difference. Therefore, an effect on bone of antiretroviral drugs does not explain why a plasma viral load < 500 copies/ml arose as a risk factor for the osteoporotic men.
The potential effect of CD4 cell count nadir has been studied previously among HIV-positive women and was not recognized as a factor associated with weakening osteopathies . Such a linkage in our study is an original finding. CD4 cell count nadir is directly linked to the severity and length of immunosuppression. This suppression will lead to immunological disorders and an increase in proinflammatory cytokines, inducing modifications of bone tissue metabolism at the beginning of an early demineralization. Another possible explanation of the effect of the CD4 cell nadir observed is that patients with a low CD4 cell nadir are those who have been treated for a longer period with antiretroviral drugs. This would also indirectly support a negative role for antiretroviral drugs on bone metabolism.
The cumulated exposure to PI drugs was significantly associated with bone abnormalities in univariate analysis, as seen by Nolan et al.  and Moore et al. , but this factor was not significant in the multivariate model. Finally, neither lipodystrophy nor reduced physical activity was associated with early demineralization.
In consideration of the high frequency of diagnosed osteoporosis, it would be useful to propose osteodensitometry for HIV-infected patients in a targeted way: that is for patients with both the traditional risk factors of osteoporosis and the specific risk factors of HIV infection highlighted in this study. Moreover, our analysis indicates a cortical prevalence of bone demineralization, especially for men; consequently, particularly vigilant is suggested for this risk, in particular for femoral neck fractures.
Ongoing studies will provide better knowledge of the physiopathological mechanisms at the initiation of early demineralization among HIV-infected patients, thus allowing better diagnostic, preventive and therapeutic evaluation to support care for this chronic infection in the coming years.
Composition of the Groupe d'Epidémiologie Clinique du SIDA en Aquitaine. C. Cazanave, M. Dupon, V. Lavignolle-Aurillac, N. Barthe, S. Lawson-Ayayi, H. Dutronc, N. Mehsen, T. Schaeverbeke, P. Mercie. P. Morlat, J.L. Pellegrin, R. Thiébaut and F. Dabis (TISSOS Study Group); F. Dabis (Coordinator); G. Chêne, F. Dabis, S. Lawson-Ayayi, C. Lewden, R. Thiébaut (epidemiology and methodology); M. Bonarek, F. Bonnal, F. Bonnet, N. Bernard, O. Caubet, L. Caunègre, J. Ceccaldi, C. De La Taille, S. de Witte, M. Dupon, H. Dutronc, S. Farbos, T. Galpérine, K. Lacombe, D. Lacoste, S. Lafarie, P. Loste, D. Malvy, P. Mercié, P. Morlat, D. Neau, A. Ochoa, J.L. Pellegrin, J.M. Ragnaud, S. Tchamgoué, J.F. Viallard (infectious diseases and internal medicine); P. Blanco, J.F. Moreau (immunology); H. Fleury, M.E. Lafon, B. Masquelier, I. Pellegrin (virology); D. Breilh (pharmacology); G. Miremont-Salamé (pharmacovigilance); E. Balestre, M.J. Blaizeau, M. Decoin, S. Delveaux, S. Geffard, C. Hannapier, S. Labarrère, V. Lavignolle-Aurillac, B. Uwamaliya-Nziyumvira (data collection and data management); G. Palmer, D. Touchard (data processing).
Note: Preliminary results have been presented in part at the Third International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, July 2005 [abstract TuPe2.2B19] and at the Thirteenth Conference on Retroviruses and Opportunistic Infections. Denver, February 2006 [abstract 229].
This study was supported by a grant from Ensemble contre le SIDA/SIDACTION (15th call for proposals). The Aquitaine cohort is supported by a multiyear grant of the French Agency for Research on AIDS and viral Hepatitis (ANRS).
1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al
. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853–860.
2. Carr A, Samaras K, Burton S, Law M, Freund J, Chrisolm DJ, et al
. A syndrome of peripheral lipodystrophy, hyperlipidemia and insuline resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51–F58.
3. Tebas P, Poxderly WG, Claxton S, Marin D, Tantisiriwat W, Teitebaulm SL, et al
. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000; 14:F63–F67.
4. Knobel H, Guelar A, Valecillo G, Nogues X, Diez A. Osteopenia in HIV-infected patients: is it the disease or is it the treatment? AIDS 2001; 15:807–808.
5. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20:2165–2174.
6. Mondy K, Tebas P. Emerging bone problems in patients infected with human immunodeficiency virus. Clin Infect Dis 2003; 36(Suppl 2):S101–S105.
7. Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, DeMarco D, et al
. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 2003; 36:482–490.
8. McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, Shevitz AH. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study. Clin Infect Dis 2005; 41:1662–1670.
9. Bongiovanni M, Fausto A, Cicconi P, Aliprandi A, Cornalba G, Bini T, et al
. Nonnucleoside-reverse-transcriptase-inhibitor-based HAART and osteoporosis in HIV-infected subjects. J Antimicrob Chemother 2006; 58:485–486.
10. Amorosa V, Tebas P. Bone disease end HIV infection. Clin Infect Dis 2006; 42:108–114.
11. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Santoro N, Schoenbaum EE. HIV infection and bone mineral density in middle-aged women. Clin Infect Dis 2006; 42:1014–1020.
12. Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, et al
. Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy. Clin Endocrinol 2006; 65:191–197.
13. Overton ET, Mondy K, Bush T, Conley L, Kojic E, Henry K, et al. Factors associated with low bone mineral density in a large cohort of HIV-infected US adults: baseline results from the SUN Study. 14th Conference on Retroviruses and Opportunistic Infections
. Los Angeles, February 2007 [abstract 836].
14. Kühne CA, Heufelder AM, Hofbauer LC. Bone and mineral metabolism in human immunodeficiency virus infection. J Bone Miner Res 2001; 16:2–9.
15. Fessel WJ, Hurley LB. Is HIV sequestered in bone? Possible implications of virological and immunological findings in some HIV-infected patients with bone disease. AIDS 2003; 17:255–257.
16. Cozzolino M, Vidal M, Arcidiacono MV, Tebas P, Yarashesky KE, Dusso AS. HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS 2003; 17:513–520.
17. Amiel C, Ostertag A, Slama L, Baudoin C, N'Guyen T, Lajeunie E, et al
. BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res 2004; 19:402–409.
18. Fausto A, Bongiovanni M, Cicconi P, Menicagli L, Ligabo EV, Melzi S, et al
. Potential predictive factors of osteoporosis in HIV-positive subjects. Bone 2006; 38:893–897.
19. Thiebaut R, Morlat P, Jacqmin-Gadda H, Neau D, Mercie P, Dabis F, et al
. Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d'Epidémiologie du SIDA en Aquitaine (GECSA). AIDS 2000; 14:971–978.
20. Kelly T. Bone mineral density reference databases for American men and women. J Bone Miner Res 1990; 5(Suppl 2):S249.
21. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994; 4:368–381.
22. Nolan D, Upton R, McKinnon E, John M, James I, Adler B, et al
. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 2001; 15:1275–1280.
23. Moore AL, Vashisht A, Sabin CA, Mocroft A, Madge S, Phillips AN, et al
. Reduced bone mineral density in HIV-positive individuals. AIDS 2001; 15:1731–1733.
24. Carr A, Miller J, Eisman JA, Cooper DA. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight preantiretroviral therapy. AIDS 2001; 15:703–709.
25. Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 2003; 17:1917–1923.
26. Dolan SE, Huang JS, Killilea KM, Sullivan MP, Aliabadi N, Grinspoon S. Reduced bone density in HIV-infected women. AIDS 2004; 18:475–483.
27. Brown TT, Ruppe MD, Kassner R, Kumar P, Kehoe T, Dobs AS, et al
. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab 2004; 89:1200–1206.
28. Seminari E, Castagna A, Soldarini A, Galli L, Fusetti G, Dorigatti F, et al
. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. HIV Med 2005; 6:145–150.
29. Konishi M, Takahashi K, Yoshimoto E, Uno K, Kasahara K, Mikasa K. Association between osteopenia/osteoporosis and the serum RANKL in HIV-infected patients. AIDS 2005; 19:1240–1241.
30. Bongiovanni M, Fausto A, Cicconi P, Menicagli L, Melzi S, Ligabo VE, et al
. Osteoporosis in HIV-infected subjects: a combined effect of highly active antiretroviral therapy and HIV itself? J Acquir Immune Defic Syndr 2005; 40:503–504.
31. Garcia Aparicio AM, Munoz Fernandez S, Gonzalez J, Arribas JR, Pena JM, Vazquez JJ, et al
. Abnormalities in the bone mineral metabolism in HIV-infected patients. Clin Rheumatol 2006; 25:537–539.
32. Guaraldi G, Ventura P, Albuzza M, Orlando G, Bedini A, Amorico G, et al
. Pathological fractures in AIDS patients with osteopenia and osteoporosis induced by antiretroviral therapy. AIDS 2001; 15:137–138.
33. Yin M, Dobkin J, Brudney K, Becker C, Zadel JL, Manandhar M, et al
. Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos Int 2005; 16:1345–1352.
Keywords:© 2008 Lippincott Williams & Wilkins, Inc.
bone mineral density; HIV; osteopenia; osteoporosis